17 Nov
2023
16:30 E.S.T.

Cellectis’ Shareholders Meeting to be Held on December 22, 2023

Read more

15 Nov
2023
02:30 E.S.T.

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Read more

06 Nov
2023
16:30 E.S.T.

Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023

Read more

02 Nov
2023
16:30 E.S.T.

Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting

Read more

01 Nov
2023
16:30 E.S.T.

Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023

Read more

01 Nov
2023
03:00 E.S.T.

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca

Read more

31 Oct
2023
16:30 E.S.T.

Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Read more

24 Oct
2023
16:30 E.S.T.

Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress

Read more

12 Oct
2023
04:30 E.S.T.

Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Δ Syndrome Type 1 (APDS1)

Read more

27 Sep
2023
16:30 E.S.T.

Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Read more